Giovanna Leone, Valentina Baldini, Stefania Bramanti, Roberto Crocchiolo, Salvatore Gattillo, Stefano Ermini, Valeria Giudice, Ivana Ferrero, Tiziana Moscato, Raffaella Milani, Maria Gozzer, Nicola Piccirillo, Cristina Tassi, Valter Tassi, Paola Coluccia
Chimeric antigen receptor (CAR) T-cell therapy relies on T cells engineered to target specific tumor antigens such as CD-19 in B-cell malignancies. In this setting, the commercially available products have offered a potential long-term cure for both pediatric and adult patients. Yet manufacturing CAR T cells is a cumbersome, multistep process, the success of which strictly depends on the characteristics of the starting material, i.e., lymphocyte collection yield and composition. These, in turn, might be affected by patient factors such as age, performance status, comorbidities, and previous therapies...
February 23, 2023: Blood Transfusion